Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis
- PMID: 28264848
- PMCID: PMC5404581
- DOI: 10.1128/AAC.02418-16
Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis
Abstract
Among the viridans group streptococci, the Streptococcus mitis group is the most common cause of infective endocarditis. These bacteria have a propensity to be β-lactam resistant, as well as to rapidly develop high-level and durable resistance to daptomycin (DAP). We compared a parental, daptomycin-susceptible (DAPs) S. mitis/S. oralis strain and its daptomycin-resistant (DAPr) variant in a model of experimental endocarditis in terms of (i) their relative fitness in multiple target organs in this model (vegetations, kidneys, spleen) when animals were challenged individually and in a coinfection strategy and (ii) their survivability during therapy with daptomycin-gentamicin (an in vitro combination synergistic against the parental strain). The DAPr variant was initially isolated from the cardiac vegetations of animals with experimental endocarditis caused by the parental DAPs strain following treatment with daptomycin. The parental strain and the DAPr variant were comparably virulent when animals were individually challenged. In contrast, in the coinfection model without daptomycin therapy, at both the 106- and 107-CFU/ml challenge inocula, the parental strain outcompeted the DAPr variant in all target organs, especially the kidneys and spleen. When the animals in the coinfection model of endocarditis were treated with DAP-gentamicin, the DAPs strain was completely eliminated, while the DAPr variant persisted in all target tissues. These data underscore that the acquisition of DAPr in S. mitis/S. oralis does come at an intrinsic fitness cost, although this resistance phenotype is completely protective against therapy with a potentially synergistic DAP regimen.
Keywords: Streptococcus mitis group; daptomycin; experimental endocarditis; fitness; gentamicin; high-level daptomycin resistance; virulence.
Copyright © 2017 American Society for Microbiology.
Figures

Similar articles
-
Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.Antimicrob Agents Chemother. 2019 May 24;63(6):e00386-19. doi: 10.1128/AAC.00386-19. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30962347 Free PMC article.
-
Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance.Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0147222. doi: 10.1128/aac.01472-22. Epub 2023 Mar 6. Antimicrob Agents Chemother. 2023. PMID: 36877026 Free PMC article.
-
Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.Antimicrob Agents Chemother. 2013 May;57(5):2319-25. doi: 10.1128/AAC.01921-12. Epub 2013 Mar 11. Antimicrob Agents Chemother. 2013. PMID: 23478959 Free PMC article.
-
Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy.Clin Infect Dis. 2001 Aug 15;33(4):577-9. doi: 10.1086/321910. Epub 2001 Jul 6. Clin Infect Dis. 2001. PMID: 11462199 Review.
-
Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.Int J Antimicrob Agents. 2011 Nov;38(5):365-70. doi: 10.1016/j.ijantimicag.2010.11.038. Epub 2011 Mar 21. Int J Antimicrob Agents. 2011. PMID: 21420835 Review.
Cited by
-
Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.Antimicrob Agents Chemother. 2019 May 24;63(6):e00386-19. doi: 10.1128/AAC.00386-19. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30962347 Free PMC article.
-
Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis.Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01531-18. doi: 10.1128/AAC.01531-18. Print 2019 Feb. Antimicrob Agents Chemother. 2019. PMID: 30509945 Free PMC article.
-
Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance.Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0147222. doi: 10.1128/aac.01472-22. Epub 2023 Mar 6. Antimicrob Agents Chemother. 2023. PMID: 36877026 Free PMC article.
-
Multiple Recurrent Infective Endocarditis Secondary to Streptococcus mitis Bacteremia Despite Proper Antibiotic and Surgical Treatment.Cureus. 2023 May 13;15(5):e38981. doi: 10.7759/cureus.38981. eCollection 2023 May. Cureus. 2023. PMID: 37378097 Free PMC article.
-
Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0252220. doi: 10.1128/AAC.02522-20. Epub 2021 Jul 12. Antimicrob Agents Chemother. 2021. PMID: 34252304 Free PMC article.
References
-
- Fowler VG, Scheld WM, Bayer AS. 2015. Endocarditis and intravascular infections, p 990–1028. In Principles and practices of infectious diseases. Elsevier Inc, Amsterdam, The Netherlands.
-
- Shelburne SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV. 2014. Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis 59:223–230. doi:10.1093/cid/ciu260. - DOI - PubMed
-
- Ahmed R, Hassall T, Morland B, Gray J. 2003. Viridans streptococcus bacteremia in children on chemotherapy for cancer: an underestimated problem. Pediatr Hematol Oncol 20:439–444. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases